

A² cont. 10. small bowel irritation, nausea and vomiting, comprising administering to said subject a side-effect reducing amount of a selective cyclooxygenase-2 inhibitor.

10. (New) The method of claim 1, wherein the cyclooxygenase-2 inhibitor is administered orally, topically, parenterally, or by inhalation spray.

11. (New) The method of claim 1, wherein the cyclooxygenase-2 inhibitors is administered as a tablet, troche, lozenge, aqueous or oily suspension, dispersible powder or granule, emulsion; hard or soft capsule, syrup or elixer.

12. (New) The method of claim 1, wherein the cyclooxygenase-2 inhibitor is administered in a dosage amount of about 0.01 to 200 mg/kg of body weight of the subject.

REMARKS

The Official Action of April 24, 2002 has been carefully considered. Accordingly the amendments presented herewith for the application, taken with the following remarks, are believed sufficient to place the application in condition for allowance.

By this amendment, the specification was objected to on the ground that two separate headings on page 2 referred to a detailed description of the invention. The Examiner is correct and by this amendment the first heading prior to paragraph 09 has been changed to "Brief Description of the Drawings". Accordingly, reconsideration is requested.